Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of G1 Therapeutics, Inc.
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of G1 Therapeutics, Inc. since year 2005.
Table 2 shows the detailed insider transactions of G1 Therapeutics, Inc. since 2005.
The reporting company's ticker symbol is GTHX. The reporting company's CIK number is 1560241.
The total value of stock buying since 2005 is $18,424,995.
The total value of stock sales since 2005 is $0.
The total value of stock option exercises since 2005 is $0.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2017-05-22||Eshelman Ventures, Llc (10% Owner)||Buy||300,000||15.00||4,500,000|
|2017-05-22||Medimmune Ventures, Inc. (10% Owner)||Buy||75,000||15.00||1,125,000|
|2017-05-22||Reed Douglas Md (10% Owner)||Buy||133,333||15.00||1,999,995|
|2017-05-22||Muir Glenn P (Director)||Buy||20,000||15.00||300,000|
|2017-05-22||Eshelman Fredric N (Director)||Buy||300,000||15.00||4,500,000|
Insider trading activities including stock purchases, stock sales, and option exercises of GTHX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of G1 Therapeutics, Inc. (symbol GTHX, CIK number 1560241) see the Securities and Exchange Commission (SEC) website.